Loading stock data…
Aspire Biopharma Holdings (ASBP)
$6.24+0.24 (+3.97%)
Market OpenUpdated 1:58 PM EDT
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aspire Biopharma Holdings, Inc. in the Healthcare sector is trading at $6.24 with a market capitalization of $8M. The stock is currently near its 52-week low of $0.11, remaining 15.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $28,353↑ | $4,261↑ | $1,941 | $0 | $0 |
| Gross Profit | $5,750↑ | -$1,000↓ | $884 | — | $0 |
| Operating Income | -$1.65M↑ | -$1.85M↓ | -$1.15M↓ | -$799,890↑ | -$15.56M |
| Net Income | -$3.22M↑ | -$4.71M↓ | -$1.85M↑ | -$1.98M↑ | -$15.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.65M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-304.06%
Volume
Today's trading volume
27,161
Recent News
Aspire Biopharma Acquires Automotive Supplier Dura Driver Control Systems in $30M Deal (ASBP)
Aspire Biopharma has agreed to acquire Dura Driver Control Systems, a global automotive supplier with more than $200 million in annual revenue, significantly reshaping the company’s revenue base and business mix. Key Investor TakeawaysAspire Biopharma (NASDAQ:ASBP) has signed a definitive agreement to acquire Dura Driver Control Systems for $30 million in cash.
ASBP Stock Heads For Best Week In Over 2 Months – Why This Drug Delivery Tech Firm Is Buying An Auto Supplier?
The company announced the acquisition of Dura Driver Control Systems for $30 million in cash.
Aspire Biopharma (ASBP) Authorizes $5M Share Repurchase Program
Aspire Biopharma Holdings (NASDAQ:ASBP) is one of the worst performing NASDAQ stocks so far in 2026. On April 27, Aspire Biopharma authorized a $5 million share repurchase program using existing cash. The board initiated the buyback due to confidence in the company’s financial strength, its drug development pipeline, and the potential value of its pending […]
Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages
Aspire Biopharma (ASBP) wholly owned subsidiary, Buzz Bomb Caffeine Company, announced a strategic brand management and distribution agreement with Blue Shark Beverages. Effective February 1, the relationship is expected to drive the retail expansion of BUZZ BOMB, a proprietary 50mg sublingual caffeine stick pack in four flavors, across key Southern California markets. The rollout will debut in Palm Springs and surrounding cities in the Coachella Valley, followed by a phased expansion into the L
Aspire files patent application for clopidogrel sublingual powder formulation
Aspire Biopharma (ASBP) announced the filing of a new provisional patent application with the United States Patent and Trademark Office. The application, titled “A Sublingual Powder Formulation of Clopidogrel and Methods of Use Thereof,” covers the first-ever sublingual formulation of clopidogrel, the active pharmaceutical ingredient in the widely prescribed blood thinner Plavix. This development represents a series of sublingual-based therapeutic alternatives the Company intends to commercializ